Table 2. Clinical responses of patients.

Trial number	Clinical risk group	Interval from last chemo to vaccination	Immune response group	No. of prior relapses	Disease at study entry	Subsequent course	Current status	FU a (m)	Date of last FU info
3	1	24	I	0	NMD	Never relapsed	ADF	45	09/04/02
21	1	16	I	2	NMD	Never relapsed	ADF	34	11/11/2000
26	1	21	I	0	NMD	Never relapsed	ADF	28	27/12/2001
28	2	25	I	0	NMD	Never relapsed	ADF	24	03/02/2003
6	1	14	I	2	NMD	Nodal and bone relapse	DOD	18	18/10/2001
12	1	12	I	0	NMD	Two further relapses	DOD	26	17/10/2000
22	1	22	I	2	Equivocal PD in lungs on CT	PD lungs	DOD	18	04/12/2002
24	1	12	I	3	Macroscopic residue	Local recurrence and lung mets	DOD	4	25/11/2002
9	1	22	II	0	Residual inoperable primary & metastatic disease	No further progressions	ADF	49	06/10/2003
17	1	22	II	1	NMD	No further relapse	ADF	33	26/06/2003
23	2	25	II	0	NMD	Never relapsed	ADF	31	20/07/2001
20	1	21	II	2	NMD	PD lungs	AWD	34	17/10/2002
7	1	20	II	1	Local recurrence	Local PD	DOD	6	27/01/2003
16	2	14	II	0	NMD	Two further relapses (lung and abdo)	DOD	19	20/11/2002
31	1	12	II	2	NMD	One further relapse	DOD	8	02/10/2001
1	2	21	III	0	NMD	pulm mets during vaccination	ADF	61	26/10/2003
5	1	27	III	1	NMD	No further relapse	ADF	45	02/01/03
10	1	25	III	1	NMD	Two skin relapses in thoracotomy scar	ADF	32	17/02/2000
11	2	8	III	0	NMD	Never relapsed	ADF	44	01/01/2003
29	2	18	III	0	NMD	Never relapsed	ADF	26	12/09/2001
2	1	19	III	3	NMD	Relapsed, Feb 2002	AWD	50	20/06/2002
4	1	11	III	2	NMD	Further pulm relapse	DOD	10	26/06/2003
8	1	11	III	0	NMD	Three further relapses	DOD	25	13/11/2002
13	1	9	III	1	NMD	One further relapse	DOD	36	24/05/2001
14	1	7	III	1	NMD	Further pulm relapse	DOD	17	13/02/2000
15	1	22	III	4	PD	Continued PD	DOD	2	22/06/2001
18	1	9	III	1	NMD	Local recurrence, then mediastinal recurrence, further local recurrence	DOD	16	07/07/2001
27	1	23	III	2	NMD	Pulmonary relapse	DOD	7	04/02/2003

NMD=no measurable disease; PD=progressive disease.

^aFU is months from study entry.